Company news
Hemostemix Inc (TSXV:HEM) news
Hemostemix Inc news releases on 6ix. Latest, Aug 30, 2022: Hemostemix Announces Phase II Results Plus New Heart Study Demonstrating Statistically Significant…
Press releases — page 4
Hemostemix Announces Phase II Results Plus New Heart Study Demonstrating Statistically Significant Improvement in Ejection Fraction at 4 and 12 Months after ACP-01 Heart Injections
August 30, 2022
Hemostemix Announces Closing of UNIT Private Placement
August 22, 2022
Hemostemix Announces Closing of Second Tranche of UNIT Private Placement
August 12, 2022
Hemostemix Announces the Incorporation of PreCerv Inc. And a Global Field of Use License to NCP-01
June 14, 2022
Hemostemix Announces Financing
May 19, 2022
Hemostemix Announces Pete Pavlin, P.Eng., Vice-President Operations
May 19, 2022
Hemostemix Announces Rick Groome as Special Advisor to The CEO
May 16, 2022
Hemostemix Announces Its Intellectual Property is Back Home
May 10, 2022
Hemostemix Announces Closing of $2,750,000
April 25, 2022
Hemostemix Inc. Announces Intellectual Property Due Diligence and Data Audit Completed
April 12, 2022
Hemostemix Announces Settlement Agreement
March 23, 2022
Hemostemix: Interest Payment on Convertible Debenture
March 3, 2022
Hemostemix Announces $2,750,000 Convertible Debenture
March 2, 2022
Hemostemix Announces Stock Options Grant
March 1, 2022
Your Fountain of Youth Trademarked by Hemostemix
February 14, 2022
Hemostemix Partners with My Next Health, Obtains USD $150,000 Subscription at CAD $0.25 Per Unit, and Incorporates Functional Genomics
January 21, 2022
Hemostemix to Combine ACP-01 with Dr. James Shapiro's Islet Cells to Treat Type 1 Diabetes
January 11, 2022
Virtual Conference for Life Sciences Companies Broadcast Live December 16th
December 14, 2021
Hemostemix Announces Soft Lock of Database as Source Document Verification Completed
December 9, 2021
Hemostemix Confirms OTCQB Listing
October 28, 2021
Hemostemix Confirms OTCQB Application is Filed
October 19, 2021
Hemostemix Announces Dr. Fraser C. Henderson Sr., MD, as Chief Medical Officer
October 14, 2021
Hemostemix Announces the Second Stem Cell Recipient Interview: One Week to No Chest Pain
October 4, 2021
Hemostemix Announces Closing of First Tranche of Unit Private Placement
September 21, 2021
Hemostemix Announces the First of a Series of 2021 Video Interviews with ACP-01 Recipients: What the Successful Compassionate Treatment of Ischemic Cardiomyopathy Looks Like After 13 Years
September 14, 2021
Hemostemix Announces Five Million Unit Private Placement
September 8, 2021
Hemostemix Provides Update of Phase II Clinical Trial, 9th Circuit Court Decision Including Cost Award and its Annual General Meeting Results
July 6, 2021
Hemostemix Announces Warrant Repricing and Extension
July 5, 2021
Peter Lacey Increases His Investment in Hemostemix Inc.
June 20, 2021
Hemostemix Announces the Closing of a $2,500,000 Convertible Debenture
June 11, 2021
Hemostemix Announces that, Due to the COVID-19 Pandemic, the Annual and Special Meeting Will Only Be Held via Zoom and Shareholders are Requested to Follow the Meeting Instructions Mailed to the Shareholders of Record
May 31, 2021
Hemostemix Announces the TSX Venture's Preliminary Approval of the Closing of a $2,500,000 Convertible Debenture at $0.40 per Unit and Corporate Update
May 29, 2021
Hemostemix to Present at the Emerging Growth Conference
May 25, 2021
Hemostemix Announces Closing of Unit Private Placement
May 9, 2021
Hemostemix Provides a Clinical Trial Update and Announces the Release and Filing of 2020 Year-end Audited Financial Statements and Management Discussion and Analysis
April 29, 2021
Hemostemix Reprices and Amends the Terms of Its Unit Offering and Debenture Offering
April 26, 2021
Hemostemix Announces Completion of Phase II Clinical Trial Subject Follow Up and HMTXF Up-list
April 23, 2021
Hemostemix Announces a $2,500,000 Lead Order and its Clinical Trial and Litigation Updates
April 8, 2021
Hemostemix Announces It Is Trading on the Frankfurt Stock Exchange and It Has Retained HE Capital Markets Ltd.
April 8, 2021
Hemostemix Announces Clinical Trial Update and Contract with GlobeX Data to Encrypt its Communications with Regulatory Authorities
March 18, 2021
Hemostemix Announces the Protocol First Contract and Warrant Repricing Approval
February 11, 2021
Hemostemix Announces HS 12 - 01 Clinical Trial Completion of Subjects' Follow-Up Visits at the End of March and Warrants Extended and Repriced
January 28, 2021
Hemostemix Announces the Bread Contract with the Department of Foreign Affairs, Trade & Development Canada
January 22, 2021
Hemostemix Announces Private Placement Update
December 29, 2020
Hemostemix Announces Corporate Update
December 22, 2020
Hemostemix Announces Closing of Existing Private Placement and Announces a New Private Placement
December 18, 2020
InvestmentPitch Media Video Discusses Hemostemix Successfully Obtaining all Clinical Trial Data and Announcement of $2.5 Million Unit Offering - Video Available on Investmentpitch.com
December 1, 2020
Hemostemix Files Its Unaudited Condensed Consolidated Interim Financial Statements and Management Discussion and Analysis for the Three Months Ended March 31, 2020
July 13, 2020
Hemostemix Files Its Audited Annual Financial Statements and Management Discussion and Analysis for the Period Ending December 31, 2019
July 9, 2020
Hemostemix Announces Closing of Private Placement
July 9, 2020